Acquired G2032R Resistance Mutation in ROS1 to Lorlatinib Therapy Detected with Liquid Biopsy

Lorlatinib, a third-generation anaplastic lymphoma kinase (ALK)/receptor tyrosine kinase inhibitor (ROS1), demonstrated efficacy in ROS1 positive (ROS1+) non-small cell lung cancer (NSCLC), although approval is currently limited to the treatment of ALK+ patients. However, lorlatinib-induced resistan...

Descripción completa

Detalles Bibliográficos
Autores principales: Jóri, Balázs, Falk, Markus, Hövel, Iris, Weist, Peggy, Tiemann, Markus, Heukamp, Lukas C., Griesinger, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9497554/
https://www.ncbi.nlm.nih.gov/pubmed/36135089
http://dx.doi.org/10.3390/curroncol29090520

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9497554/
https://www.ncbi.nlm.nih.gov/pubmed/36135089
http://dx.doi.org/10.3390/curroncol29090520

Ejemplares similares